Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Silvio Inzucchi MD

Silvio E. Inzucchi MD

Professor of Medicine (Endocrinology); Clinical Director, Section of Endocrinology; Director, Yale Diabetes Center; Director, Endocrinology and Metabolism Fellowship, Yale School of Medicine, New Haven, Connecticut

Dr. Silvio Inzucchi is Professor of Medicine at the Yale University School of Medicine in New Haven, Connecticut, where he serves as the Clinical Chief of the Section of Endocrinology, Program Director of the Endocrinology and Metabolism Fellowship, and Medical Director of the Yale Diabetes Center.

Dr. Inzucchi has been an invited lecturer, both nationally and internationally, on many topics, most pertaining to clinical diabetes management. He has authored or coauthored more than 500 manuscripts, chapters, and abstracts, some published in the foremost medical journals, including The New England Journal of Medicine and JAMA. He has served on editorial boards for numerous scientific journals, including Diabetes Care and the Journal of Clinical Endocrinology & Metabolism.

Dr. Inzucchi has a large academic clinical practice involving a wide spectrum of patients with endocrine diseases, with a focus on diabetes and pituitary/adrenal diseases. His current research interests include anti-hyperglycemic therapy in both the inpatient and outpatient settings and the link among type 2 diabetes, insulin resistance, and cardiovascular complications.

Disclosures

  • Consultant/clinical trial committees: AstraZeneca; Boehringer Ingelheim; Novo Nordisk; Merck; Pfizer; Bayer
  • Lectures: AstraZeneca; Boehringer Ingelheim

Recent Contributions to PracticeUpdate:

  1. Semaglutide vs Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise
  2. ADA 2018: Clinically Relevant Data on Pioglitazone and CV Risk Reduction
  3. Risk of Amputations Associated With SGLT2 Inhibitors Compared With DPP-4 Inhibitors
  4. Modifying Diabetes Drug Therapy in the Presence of Renal Disease
  5. ADA 2018: Critical Changes in the New ADA Guidelines for Type 2 Diabetes
  6. ADA Scientific Sessions 2018: Recommendations From Dr. Silvio Inzucchi
  7. Metabolic Syndrome Is Associated With Lower Neurocognitive Function in Middle-Aged Hispanics/Latinos
  8. The Risk of Acute Pancreatitis After Initiation of DPP-4 Inhibitors
  9. Rising Economic Costs of Diabetes
  10. PCSK9 Monoclonal Antibodies Do Not Significantly Affect New-Onset Diabetes or Glucose Metabolism

Most Read This Week

Recently Updated